CA3117853A1 - Novel rationally designed protein compositions - Google Patents
Novel rationally designed protein compositions Download PDFInfo
- Publication number
- CA3117853A1 CA3117853A1 CA3117853A CA3117853A CA3117853A1 CA 3117853 A1 CA3117853 A1 CA 3117853A1 CA 3117853 A CA3117853 A CA 3117853A CA 3117853 A CA3117853 A CA 3117853A CA 3117853 A1 CA3117853 A1 CA 3117853A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- fusion protein
- antibody
- polypeptide
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752293P | 2018-10-29 | 2018-10-29 | |
| US62/752,293 | 2018-10-29 | ||
| US201962811116P | 2019-02-27 | 2019-02-27 | |
| US62/811,116 | 2019-02-27 | ||
| PCT/CN2019/114026 WO2020088459A1 (en) | 2018-10-29 | 2019-10-29 | Novel rationally designed protein compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117853A1 true CA3117853A1 (en) | 2020-05-07 |
Family
ID=70462528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117853A Pending CA3117853A1 (en) | 2018-10-29 | 2019-10-29 | Novel rationally designed protein compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12378295B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873945A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7496091B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210087965A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166272B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019371994A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008204A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117853A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004916A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202104297XA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI840433B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020088459A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020038379A1 (en) * | 2018-08-20 | 2020-02-27 | 1Globe Biomedical Co., Ltd. | Novel cancer immunotherapy antibody compositions |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| CN115916831A (zh) * | 2020-06-30 | 2023-04-04 | Gi 医诺微新 | 包含抗lag-3抗体和il-2的融合蛋白及其用途 |
| JP7819944B2 (ja) * | 2020-07-09 | 2026-02-25 | ユーティレックス カンパニー リミテッド | Il-2バリアント |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| CN120518765A (zh) * | 2025-02-08 | 2025-08-22 | 龙启生物科技(上海)有限公司 | 一种结合人CD8β的VHH及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| CN107915777A (zh) * | 2016-10-09 | 2018-04-17 | 泰州迈博太科药业有限公司 | 一种重组免疫细胞因子及其应用 |
| JP7148539B2 (ja) | 2017-04-03 | 2022-10-05 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| KR102461885B1 (ko) * | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
-
2019
- 2019-10-29 CA CA3117853A patent/CA3117853A1/en active Pending
- 2019-10-29 WO PCT/CN2019/114026 patent/WO2020088459A1/en not_active Ceased
- 2019-10-29 MX MX2021004916A patent/MX2021004916A/es unknown
- 2019-10-29 AU AU2019371994A patent/AU2019371994A1/en not_active Abandoned
- 2019-10-29 BR BR112021008204-2A patent/BR112021008204A2/pt not_active IP Right Cessation
- 2019-10-29 JP JP2021547634A patent/JP7496091B2/ja active Active
- 2019-10-29 KR KR1020217016193A patent/KR20210087965A/ko not_active Abandoned
- 2019-10-29 US US17/288,273 patent/US12378295B2/en active Active
- 2019-10-29 EP EP19878076.9A patent/EP3873945A4/en active Pending
- 2019-10-29 SG SG11202104297XA patent/SG11202104297XA/en unknown
- 2019-10-29 TW TW108139140A patent/TWI840433B/zh active
- 2019-10-29 CN CN201980071932.6A patent/CN113166272B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873945A4 (en) | 2022-12-28 |
| US20210388049A1 (en) | 2021-12-16 |
| WO2020088459A1 (en) | 2020-05-07 |
| TW202035440A (zh) | 2020-10-01 |
| US12378295B2 (en) | 2025-08-05 |
| CN113166272A (zh) | 2021-07-23 |
| MX2021004916A (es) | 2021-06-18 |
| EP3873945A1 (en) | 2021-09-08 |
| TWI840433B (zh) | 2024-05-01 |
| BR112021008204A2 (pt) | 2021-08-10 |
| SG11202104297XA (en) | 2021-05-28 |
| CN113166272B (zh) | 2024-07-23 |
| KR20210087965A (ko) | 2021-07-13 |
| JP7496091B2 (ja) | 2024-06-06 |
| JP2022512043A (ja) | 2022-02-01 |
| AU2019371994A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12378295B2 (en) | Rationally designed protein compositions | |
| CN112703205B (zh) | 抗间皮素抗体 | |
| JP2024059872A (ja) | 新規抗ccr8抗体 | |
| JP2022542543A (ja) | 抗dll3キメラ抗原受容体及びその使用 | |
| JP2020504171A (ja) | 抗PD−1抗体との組み合わせのための抗Tim−3抗体 | |
| KR20160007604A (ko) | 이중특이성 작제물 및 다양한 질병의 치료에서의 이의 용도 | |
| CN114981301B (zh) | Pd1和vegfr2双结合剂 | |
| TWI825459B (zh) | 一種SIRPα-Fc融合蛋白 | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| CA3133624A1 (en) | Cd3 binding molecules | |
| CN120058957A (zh) | 双特异性抗体 | |
| CN120731225A (zh) | Il-2融合蛋白 | |
| TW202340240A (zh) | 多特異性抗體及其藥物用途 | |
| EP3647323A1 (en) | Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| KR20250143344A (ko) | 항-cdh6 항체 및 이의 용도 | |
| CN114746451A (zh) | TGFβ/PD-L1双特异性结合蛋白 | |
| CN118647629A (zh) | 含有TNF-α的免疫缀合物及其相关方法和组合物 | |
| CN121311510A (zh) | 含有TNF-α的免疫缀合物及其相关方法和组合物 | |
| US20250019457A1 (en) | Trop2 antibodies | |
| KR20240127523A (ko) | 항-cntn4 항체 및 그의 용도 | |
| CN118215680A (zh) | 在治疗疾病中应用的多特异性抗体 | |
| US20250129175A1 (en) | CDC Platform Antibody | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| CN119173633A (zh) | 抗taa-抗cd3多特异性抗体 | |
| CN114605546A (zh) | Cd3结合分子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240806 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250829 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251029 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260102 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260429 |